{"url_path":"/sec/amlx/8-k/2026-06-04/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1658551/0001193125-26-257390-index.html","accession_number":"0001193125-26-257390","cik":"0001658551","ticker":"AMLX","issuer_name":"Amylyx Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1658551/0001193125-26-257390-index.html","primary_entity_key":"0001658551","primary_entity_name":"Amylyx Pharmaceuticals, Inc."},"word_count":375,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nAmylyx Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 4, 2026 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the three proposals set forth below, each of which is described in greater detail in the Company’s Proxy Statement, filed with the Securities and Exchange Commission on April 23, 2026. The final voting results are set forth below.\n\nProposal 1 – Election of Class II Directors\n\nThe stockholders of the Company elected each of George Mclean Milne Jr., Ph.D. and Paul Fonteyne as a Class II director of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2029 or until their successor has been duly elected and qualified or until such director’s earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class II directors were as follows:\n\n \n\nName\n\n  \nVotes For\n \n  \nVotes Withheld\n \n  \nBroker Non-Votes\n \n\nGeorge Mclean Milne Jr., Ph.D.\n\n  \n \n76,937,972\n \n  \n \n14,108,630\n \n  \n \n11,029,810\n \n\nPaul Fonteyne\n\n  \n \n86,275,670\n \n  \n \n4,770,932\n \n  \n \n11,029,810\n \n\nProposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm\n\nThe stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows:\n\n \n\nVotes For\n\n  \n\nVotes Against\n\n  \n\nAbstain\n\n  \n\nBroker Non-Votes\n\n102,036,295\n  \n34,484\n  \n5,633\n  \n0\n\nProposal 3 – Non-Binding, Advisory Vote on the Compensation of the Company’s Named Executive Officers\n\nThe stockholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers . The results of the stockholders’ vote with respect to such approval were as follows:\n\n \n\nVotes For\n\n  \n\nVotes Against\n\n  \n\nAbstain\n\n  \n\nBroker Non-Votes\n\n77,534,824\n  \n13,490,653\n  \n21,125\n  \n11,029,810\n\nNo other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \nAMYLYX PHARMACEUTICALS, INC.\n\nDate: June 4, 2026\n \n\n \nBy:\n \n\n/s/ James M. Frates\n\n \n\n \n\n \nJames M. Frates\n\n \n\n \n\n \nChief Financial Officer"}